Recently, 4 professors of HZAU were selected to the Cancer Prevention and Control Steering Committee of Wuhan “323” Campaign (a campaign against eight major health problems). Prof. Wei Shaozhong (Dean of College of Bio-medicine and Health) serves as the chairman. Prof. Jin Honglin, Researcher Li Li and part-time tutor Prof. Wu Xinhong are members of the board. Other 16 elected experts are from major hospitals, universities and primary medical units of Wuhan.
Wuhan’s “323” Campaign focuses on solving 8 major problems affecting people’s health: 3 major diseases (cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases), 2 common diseases (hypertension and diabetes), 3 public health problems (birth defects, myopia and mental health). This campaign aims to reduce the incidence, fatality rate and BOD with 3-5 years’ efforts. By 2025, resident health literacy level should surpass 35%, the mortality of cardiovascular and cerebrovascular diseases should be no higher than 2‰, and the overall 5-year survival rate of cancer should surpass 45%.
The selected experts will provide policy suggestions and technical support to the specialized disease management centers, help organizing works including training, guidance, evaluation and analysis and actively participate in them. They will carry out relevant work on scientific research, science popularization and education, technical training and academic exchanges, and cooperate with the Chronic Disease Management Center to evaluate and assess the effect of various critical actions, so as to drive the all-round development of Healthy Wuhan Action and continuously improve the Wuhan people’s sense of gain in health.

Profile
Prof. Wei Shaozhong is the Dean of College of Bio-medicine and Health of HZAU and the Director of Hubei Cancer Hospital. He is a profession who has long been engaged in the research of gastrointestinal and urinary tumors. He is one of the Young and Middle-aged Experts with Outstanding Contributions named by the National Health Commission and a talent elected to the 1st Hubei Medical Leading Talents Plan. His posts include: Chairman of Hubei Cancer Association, Chairman of Colorectal Cancer Professional Committee, Chairman of Oncology Branch of Hubei Medical Association, Executive Director of China Cancer Association and the standing member of Colorectal Cancer Professional Committee.
Prof. Jin Honglin is from the College of Bio-medicine and Health, HZAU. He has long been engaged in the research on new technologies, new targets and related immune mechanisms of tumor immunotherapy, and has a long-time concern on interdisciplinary integration and clinical transformation. He also won the Excellent Youth Fund of National Natural Science Foundation of China. Since 2019, he has published papers as corresponding author in ACS Nano, Pharmaceutical Development and Technology, Science Advances, Current Opinion in Biotechnology, Nano Today, Frontiers in Immunology and other journals.
Researcher Li Li is from the College of Bio-medicine and Health, HZAU. His research group used epigenetics, high-throughput sequencing, proteomics, cell and molecular biology, gene editing, biological information analysis as research methods to systematically study the biological functions of non-coding regions, especially non-coding RNA (such as lncrna, snoRNA), enhancer, CTCF, and DNA methylation. Since 2018, he has published papers as the first author and corresponding author in Drug Delivery and Translational Research, Nuclear Acids Res, Genome Biology and other journals.
Prof. Wu Xinhong is a part-time tutor of College of Bio-medicine and Health, HZAU, and also a chief physician of Hubei Cancer Hospital. He has been engaged in the diagnosis and treatment of breast tumors for a long time, and his main research direction is the mechanism of SRC kinase in reversing the resistance of trastuzumab and the application of quantum dot molecular probe imaging in individualized treatment of breast cancer. He has undertaken and participated in 16 national and provincial level scientific research projects, undertaken more than 10 international multi center breast cancer drug clinical trials (GCP) projects, and has obtained 1 major scientific research achievements in Hubei province. He compiled a monograph Targeted Therapy for Cancer, and published the provincial-level journal Mammary Cancer News.

Source: http://news.hzau.edu.cn/2022/0302/62673.shtml
Translated by: Du Xinjie
Supervised by: Wang Xiaoyan